AbbVie Inc. $ABBV Position Lifted by State Street Corp

AbbVie logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • State Street increased its AbbVie stake by 218,639 shares (0.3%) in the third quarter, ending with about 82.8 million shares valued at $21.7 billion. Institutional investors own 70.23% of the stock.
  • Analysts’ consensus rating is “Moderate Buy,” with an average price target of $299.62; several firms recently raised their targets, including Morgan Stanley to $346.
  • AbbVie beat quarterly earnings and revenue estimates, with revenue up 10.3% year over year, and raised its quarterly dividend to $1.82 per share from $1.73.
  • Five stocks we like better than AbbVie.

State Street Corp lifted its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 0.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 82,815,387 shares of the company's stock after purchasing an additional 218,639 shares during the quarter. AbbVie comprises 0.6% of State Street Corp's investment portfolio, making the stock its 23rd biggest holding. State Street Corp owned approximately 4.69% of AbbVie worth $21,663,677,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cornerstone Select Advisors LLC raised its holdings in AbbVie by 1.7% in the third quarter. Cornerstone Select Advisors LLC now owns 13,445 shares of the company's stock worth $3,517,000 after purchasing an additional 223 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its position in AbbVie by 102.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 2,602 shares of the company's stock valued at $681,000 after buying an additional 1,314 shares during the period. Sumitomo Life Insurance Co. lifted its position in AbbVie by 6.2% during the third quarter. Sumitomo Life Insurance Co. now owns 20,861 shares of the company's stock valued at $5,457,000 after buying an additional 1,220 shares during the period. TIAA CREF Individual & Institutional Services LLC lifted its position in AbbVie by 5.6% during the third quarter. TIAA CREF Individual & Institutional Services LLC now owns 115,515 shares of the company's stock valued at $30,218,000 after buying an additional 6,118 shares during the period. Finally, Saranac Partners Ltd boosted its holdings in shares of AbbVie by 2.6% during the 3rd quarter. Saranac Partners Ltd now owns 42,141 shares of the company's stock valued at $11,024,000 after buying an additional 1,055 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on ABBV shares. Wolfe Research raised shares of AbbVie from a "peer perform" rating to an "outperform" rating and upped their target price for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. Morgan Stanley lifted their price target on shares of AbbVie from $310.00 to $346.00 and gave the company an "overweight" rating in a research report on Monday, November 2nd. Canaccord Genuity Group lifted their price target on shares of AbbVie from $290.00 to $338.00 and gave the company a "buy" rating in a research report on Monday, November 2nd. Scotiabank boosted their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 6th. Finally, Cantor Fitzgerald upped their price objective on shares of AbbVie from $290.00 to $325.00 and gave the stock an "overweight" rating in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $299.62.

Get Our Latest Research Report on ABBV

Latest AbbVie News

Investors following ABBV have been watching these news items:

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares in the company, valued at $24,419,005.60. This trade represents a 32.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.06% of the company's stock.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $286.19 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $302.93. The company has a market cap of $505.88 billion, a P/E ratio of 49.26, a PEG ratio of 1.34 and a beta of 0.20. The stock's fifty day moving average price is $278.98 and its 200-day moving average price is $242.55.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts' consensus estimates of $3.73 by $0.09. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.86 earnings per share. On average, sell-side analysts anticipate that AbbVie Inc. will post 13.99 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a $1.82 dividend. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is a boost from AbbVie's previous quarterly dividend of $1.73. AbbVie's payout ratio is presently 119.10%.

AbbVie Company Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Read More

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines